Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atorvastatin versus aspirin versus placebo for tunneled dialysis catheter durability
IRCT20191104045328N20Phase 3Completed
- Sponsor
- Arak University of Medical Sciences
- Start
- Mar 2024
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of atorvastatin and aspirin in end-stage kidney disease (ESKD) (3 arms), sponsored by Arak University of Medical Sciences. Primary endpoints: Duration of catheter operation, Catheter infection and 2 more. Started Mar 2024; status: completed.
02
Drugs
atorvastatinaspirin
03
Conditions
end-stage kidney disease (ESKD)
Beyond the preview
Go deeper on IRCT20191104045328N20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20191104045328N20.